14 March 2018 - Scott Gottlieb, head of the FDA, has emerged as a key figure in the Trump administration’s push to lower the cost of prescription drugs.

Gottlieb has moved to the front lines of the drug pricing fight, criticizing brand-name drug manufacturers he says are trying to block competition from getting to market.

“We know that gaming goes on all the time,” Gottlieb told The Hill in a wide-ranging phone interview. “If [companies] have an opportunity to use the existing rules in ways to impede the public health goals we seek, we see them doing it. I don’t think that’s very public-health-minded. I think it’s corrosive to the overall system.”

Read The Hill article